NCT06517173 (NUWA-Y3) is a Phase 3 clinical trial of Y-3 for injection in Acute Ischemic Stroke, sponsored by Beijing Tiantan Hospital.

Who is sponsoring NCT06517173?

NCT06517173 is sponsored by Beijing Tiantan Hospital.

What drugs are being tested in NCT06517173?

Interventions in NCT06517173: Y-3 for injection, Placebo control group.

What condition does NCT06517173 study?

NCT06517173 studies Acute Ischemic Stroke.

Is NCT06517173 still recruiting?

NCT06517173 is currently recruiting now. Last updated 4 September 2024.

Last reviewed 2024-09-04 · How we verify

NCT06517173: NUWA-Y3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Y-3 in Chinese Subjects with Acute Ischemic Stroke

Recruiting now Phase 3 Last updated 4 September 2024

What this trial tests

Phase 3 trial testing Y-3 for injection in Acute Ischemic Stroke in 998 participants. Currently enrolling.

Timeline

24 July 2024

Primary endpoint
1 December 2024

1 July 2025

Quick facts

Lead sponsor	Beijing Tiantan Hospital
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	998
Start date	24 July 2024
Primary completion	1 December 2024
Estimated completion	1 July 2025
Sites	1 location across China

Drugs / interventions tested

Y-3 for injection — full drug profile →
Placebo control group

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 81, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The proportion of subjects with Modified Rankin Scale(mRS) score ≤ 1 on the 90th day of treatment
Time frame: On the 90th day of treatment
Measure the scores of subjects using the Modified Rankin Scale(mRS) scale.Measure on the 90th day of treatment to evaluate the effectiveness of the medication.The Modified Rankin Scale(mRS) score of this study ranged from 0 to 5. The higher the score, the worse the recovery, and the lower the score, the better the recovery.

Sponsor's own description

This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ischemic stroke and intervention strategies based on the timeline of stroke progression: Review and prospects.
Xu A, Zhang H, Zhang Y, Wu J, et al · · 2025 · cited 5× · PMID 41049732 · DOI 10.1016/j.apsb.2025.07.026
Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial.
Li S, Wang X, Feng B, Li H, et al · · 2025 · PMID 41344725 · DOI 10.1136/svn-2025-004582

Verify or expand the search:

Other trials of Y-3 for injection

Trials testing the same drug.

NCT06770491 — A Phase 1 Study of Y-3 in US Healthy Volunteers. · Phase 1 · completed

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06517173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
Last refreshed: 4 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06517173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing